CD4 and neoplasm: In this context, mutation-specific CD4+ T cells were shown to infiltrate the tumor and to be required for clinical efficacy, most likely by releasing proinflammatory cytokines such as interferon-γ (IFNG) and tumor necrosis factor-α (TNFA) [19, 46].